John E. Dick - Genetic Mutations

Author Information

John E. Dick is a prominent researcher affiliated with the Princess Margaret Cancer Centre at the University Health Network in Toronto, Ontario, Canada. He also holds a position in the Department of Molecular Genetics at the University of Toronto. His work is renowned in the field of genetics, particularly focusing on cancer biology and stem cell research.

Research Contributions

John E. Dick has made significant contributions to the understanding of acute myeloid leukemia (AML) and hematopoietic stem cells. His recent research in 2022 includes developing frameworks for understanding cellular hierarchies in AML, identifying miR-130a targetomes, and creating computational tools for single-molecule data analysis. Additionally, he has worked on reconstructing cancer evolutionary histories, profiling central nervous system leukemia, and improving molecular inversion probe sequencing approaches. His studies have also explored the role of INPP4B in leukemogenesis, developed novel T-cell engagers, and investigated functional heterogeneity in leukemic stem cells.

Aliases

John E. Dick is also known by several other names in different publications, including John Dick, J E Dick, J Dick, and J. Dick.

Publication and Citation Metrics

Metric	Value
Citation Count	56,763
h-index	96
Paper Count	442

Publications:

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

DOI: 10.1101/2022.01.25.476266

Year: 2022

Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML.

DOI: 10.1016/j.celrep.2022.110481

Year: 2022

SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data

DOI: 10.1093/bioinformatics/btac081

Year: 2022

Reconstructing complex cancer evolutionary histories from multiple bulk DNA samples using Pairtree.

DOI: 10.1158/2643-3230.BCD-21-0092

Year: 2022

Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target.

DOI: 10.1158/2643-3230.bcd-20-0216

Year: 2022

An improved molecular inversion probe based targeted sequencing approach for low variant allele frequency

DOI: 10.1093/nargab/lqab125

Year: 2022

INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis

DOI: 10.1101/2021.03.25.437029

Year: 2022

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo.

DOI: 10.3324/haematol.2021.279486

Year: 2022

A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell Compartment

DOI: 10.1101/2022.03.01.482535

Year: 2022

"Human, mouse and dog bone marrow show similar mesenchymal stromal cells within a distinctive microenvironment".

DOI: 10.1016/j.exphem.2021.06.006

Year: 2021

Can Mutations in Non-Coding Regions Cause Diseases?

How is Gene Amplification Detected?

What are the sources of PAH exposure?

What Are the Common Types of Errors?

How do Viral Vectors Work?

What are Neutral Mutations?

What is Genetic Diversity?

Can Missense Mutations be Treated or Repaired?

What Ethical Considerations Arise From Genetic Research?

Can Genetic Mutations from UV Radiation Be Prevented?

Partnered Content Networks

Relevant Topics